In addition, Polyphor is entitled to tiered royalty payments from Santhera's future net sales of POL6014 and to undisclosed milestone payments and royalties provided that Santhera advances the development and market entry of POL6014 in other pulmonary diseases
Chronic obstructive pulmonary disease
is most prevalent in manual labourers 68% (n: 34), followed by office staff 20% (n: 10), Shop owners 8% (n: 4%) and Homemakers 2% (n: 1).
According to Centocor, RespiVert's lead compounds -- narrow spectrum kinase inhibitors -- are advancing into clinical development as potential treatment for asthma, Chronic Obstructive Pulmonary Disease
(COPD) and Cystic Fibrosis (CF).
A study using losartan in PAH secondary to chronic obstructive pulmonary disease
was also in the acute setting and oral dosing with losartan (50 mg) produced a significant reduction in mean PAP and total pulmonary vascular resistance (8).
Even in patients without depression, pulmonary disease
should be considered a red flag, she and her colleagues conclude in the July/August Psychosomatic Medicine.
Results of a double-blind, randomized, placebo-controlled multi-center Phase III study that included 739 adult patients with chronic obstructive pulmonary disease
(COPD) were presented.
Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases
including cystic fibrosis, chronic obstructive pulmonary disease
, and pneumonia.
Specifically, they sought to evaluate whether the risk factors associated with cardiovascular and pulmonary diseases
and lung cancer occurred differently among the exposed and unexposed women, possibly indicating that adverse health effects attributed to ETS exposure might instead be caused by other factors shared by the women married to smokers.
Division Chief of Pulmonary Diseases
and Critical Care Medicine, University of North Carolina at Chapel Hill.
In addition to PAH, the company has a variety of clinical Phase II studies in pulmonary diseases
APT is a clinical-stage biopharmaceutical company developing products to treat pulmonary diseases
This effort has yielded multiple lead drug candidates that we are now profiling in a number of therapeutic areas, including hematology, metabolic disorders, autoimmune disorders, pulmonary diseases
and oncology, and we anticipate filing IND applications with the FDA on one or more of these compounds.